idraparinux

05/01/2008 - "During a 6-month extension of thromboprophylaxis, idraparinux was effective in preventing recurrent VTE but was associated with an increased risk of bleeding versus placebo. "
10/15/2016 - "In a post-hoc ancillary analysis of 'clinically relevant bleeding' events amongst 2283 patients in the idraparinux arm in the AMADEUS trial. "
01/01/2010 - "The elimination half-life of idraparinux increased to 60 days in these studies, which may explain the bleeding complications. "
05/01/2008 - "Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials."
01/01/2018 - "The data probably did not rule out a beneficial or harmful effect of idraparinux compared to VKAs on mortality at six months (RR 1.11, 95% CI 0.78 to 1.59; RD 31 more per 1000, 95% CI 62 fewer to 167 more; moderate-certainty evidence), VTE recurrence at six months (RR 0.46, 95% CI 0.16 to 1.32; RD 42 fewer per 1000, 95% CI 65 fewer to 25 more; low-certainty evidence) or major bleeding (RR 1.11, 95% CI 0.35 to 3.56; RD 4 more per 1000, 95% CI 25 fewer to 98 more; low-certainty evidence). "

09/13/2007 - "In the study of patients with deep venous thrombosis, the incidence of recurrence at day 92 was 2.9% in the idraparinux group as compared with 3.0% in the standard-therapy group (odds ratio, 0.98; 95% confidence interval [CI], 0.63 to 1.50), a result that satisfied the prespecified noninferiority requirement. "
05/01/2008 - "In its current formulation, idraparinux can be recommended only for the initial treatment of patients with deep vein thrombosis. "
05/01/2013 - "In a prospective substudy of the phase III EQUINOX trial, 228 patients treated for acute symptomatic deep vein thrombosis received idrabiotaparinux or idraparinux once weekly for 6 months. "
01/01/2011 - "We performed a randomized double-blind trial in 757 patients with symptomatic deep venous thrombosis, comparing equimolar doses of idrabiotaparinux (3 mg) with idraparinux (2.5 mg), both given subcutaneously, once weekly for 6 months. "
01/01/2003 - "A potential influence of idraparinux--a synthetic analogue of the pentasaccharide sequence in heparins--on plasma liver enzyme levels was analysed in 37 patients suffering from deep vein thrombosis and participating in the PERSIST trial. "

09/01/2008 - "Extended prophylaxis of venous thromboembolism with idraparinux."
09/13/2007 - "Of 1215 patients, 6 of 594 (1.0%) in the idraparinux group and 23 of 621 (3.7%) in the placebo group had recurrent venous thromboembolism (P=0.002). "
09/13/2007 - "Extended prophylaxis of venous thromboembolism with idraparinux."
11/01/2009 - "The efficacy of idraparinux was was proven in clinical studies with patients suffering from venous thromboembolism (VTE) or atrial fibrillation. "
05/01/2008 - "To review the evidence favoring the use of idraparinux for the acute and long-term treatment of patients with venous thromboembolism (VTE) and for the prevention of thromboembolic events in patients with atrial fibrillation (AF). "

04/01/2008 - "Idraparinux for stroke prevention in atrial fibrillation."
04/01/2004 - "This article will (a) provide an overview of the clinical trials that form the basis for current antithrombotic guidelines in patients with AF, (b) highlight the limitations of current antithrombotic drugs used for stroke prevention, (c) briefly review the pharmacology of new antithrombotic drugs under evaluation in AF, (d) describe ongoing trials with new antiplatelet therapies and idraparinux, and completed studies with ximelagatran in patients with AF, and (e) provide clinical perspective into the potential role of new antithrombotic drugs in AF."
08/01/2006 - "Of these compounds, fondaparinux is approved for the prevention and treatment of venous thromboembolism, and idraparinux is in Phase III for venous thromboembolism treatment and stroke prevention in patients with atrial fibrillation. "
09/01/2008 - "Since inhibitors of coagulation factors Xa, VII , or II a have either not been clinically tested for their efficacy for prevention of stroke from AF, did not show a comparable effect to well-established drugs, or had excess side effects (idraparinux, ximelagatran), and since mechanical devices are highly questionable concerning their long-term effect, there is currently no alternative to oral anticoagulation with vitamin K antagonists as primary or secondary stroke prevention in high-risk AF patients."
07/01/2011 - "In large clinical trials, the oral direct thrombin inhibitor ximelagatran and the long-acting factor Xa inhibitor idraparinux were effective for reducing the risk of thromboembolic stroke, but were not marketed because of liver toxicity and excessive bleeding, respectively. "

09/13/2007 - "In the study of patients with pulmonary embolism, the incidence of recurrence at day 92 was 3.4% in the idraparinux group and 1.6% in the standard-therapy group (odds ratio, 2.14; 95% CI, 1.21 to 3.78), a finding that did not meet the noninferiority requirement. "
09/13/2007 - "However, in patients with pulmonary embolism, idraparinux was less efficacious than standard therapy. "
05/01/2008 - "The administration of idraparinux in subcutaneous fixed doses of 2.5 mg once weekly was found to be as effective and safe as conventional antithrombotic therapy in the initial treatment of patients with deep vein thrombosis, but less effective than standard therapy in the initial treatment of patients with primary pulmonary embolism. "
09/13/2007 - "We conducted two randomized, open-label noninferiority trials involving 2904 patients with deep-vein thrombosis and 2215 patients with pulmonary embolism to compare the efficacy and safety of idraparinux versus standard therapy. "
01/01/2008 - "Idraparinux was noninferior to standard therapy for deep venous thrombosis but inferior for pulmonary embolism."